Johnson & Johnson $JNJ Shares Sold by First National Trust Co

First National Trust Co lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 2.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 135,898 shares of the company’s stock after selling 3,743 shares during the period. Johnson & Johnson makes up 0.9% of First National Trust Co’s investment portfolio, making the stock its 24th largest position. First National Trust Co’s holdings in Johnson & Johnson were worth $25,198,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of JNJ. Clayton Financial Group LLC purchased a new position in Johnson & Johnson in the third quarter valued at $28,000. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson during the second quarter worth approximately $27,000. Semmax Financial Advisors Inc. grew its position in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the last quarter. Compass Financial Services Inc increased its holdings in shares of Johnson & Johnson by 707.1% in the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock valued at $42,000 after acquiring an additional 198 shares during the period. Finally, Signature Resources Capital Management LLC increased its stake in Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.6%

NYSE JNJ opened at $238.62 on Tuesday. The company has a market cap of $574.90 billion, a P/E ratio of 21.59, a P/E/G ratio of 2.33 and a beta of 0.35. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $240.93. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a 50-day moving average of $214.20 and a 200-day moving average of $194.70.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, hitting the consensus estimate of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company had revenue of $24.56 billion during the quarter, compared to analyst estimates of $24.14 billion. During the same period in the prior year, the firm posted $2.04 earnings per share. The firm’s revenue was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Barclays boosted their target price on Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 30th. Morgan Stanley set a $262.00 target price on Johnson & Johnson and gave the company an “overweight” rating in a report on Wednesday, January 28th. The Goldman Sachs Group reiterated a “buy” rating and issued a $250.00 price objective on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Finally, Daiwa Securities Group boosted their target price on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research report on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.